Harvard Bioscience Past Earnings Performance
Past criteria checks 0/6
Harvard Bioscience's earnings have been declining at an average annual rate of -6.5%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 0.4% per year.
Key information
-6.5%
Earnings growth rate
-3.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -0.4% |
| Return on equity | -4.7% |
| Net Margin | -3.0% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?
Nov 26Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Revenue & Expenses BreakdownBeta
How Harvard Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 112 | -3 | 47 | 12 |
| 30 Sep 23 | 113 | -3 | 47 | 11 |
| 30 Jun 23 | 114 | -5 | 47 | 11 |
| 31 Mar 23 | 115 | -2 | 48 | 12 |
| 31 Dec 22 | 113 | -10 | 49 | 12 |
| 30 Sep 22 | 118 | -7 | 51 | 12 |
| 30 Jun 22 | 121 | -4 | 50 | 12 |
| 31 Mar 22 | 121 | -6 | 49 | 12 |
| 31 Dec 21 | 119 | 0 | 47 | 11 |
| 30 Sep 21 | 117 | -2 | 45 | 10 |
| 30 Jun 21 | 111 | -3 | 43 | 9 |
| 31 Mar 21 | 105 | -4 | 41 | 9 |
| 31 Dec 20 | 102 | -8 | 41 | 9 |
| 30 Sep 20 | 102 | -7 | 42 | 9 |
| 30 Jun 20 | 105 | -8 | 44 | 10 |
| 31 Mar 20 | 112 | -7 | 45 | 10 |
| 31 Dec 19 | 116 | -5 | 46 | 11 |
| 30 Sep 19 | 119 | -2 | 47 | 11 |
| 30 Jun 19 | 120 | 0 | 46 | 11 |
| 31 Mar 19 | 122 | -1 | 47 | 11 |
| 31 Dec 18 | 121 | -4 | 46 | 11 |
| 30 Sep 18 | 109 | -8 | 42 | 9 |
| 30 Jun 18 | 99 | -8 | 39 | 8 |
| 31 Mar 18 | 86 | -7 | 35 | 7 |
| 31 Dec 17 | 77 | -2 | 33 | 6 |
| 30 Sep 17 | 82 | -3 | 34 | 5 |
| 30 Jun 17 | 88 | -4 | 36 | 5 |
| 31 Mar 17 | 96 | -4 | 39 | 5 |
| 31 Dec 16 | 105 | -4 | 41 | 5 |
| 30 Sep 16 | 106 | -20 | 41 | 6 |
| 30 Jun 16 | 107 | -19 | 42 | 6 |
| 31 Mar 16 | 110 | -18 | 41 | 6 |
| 31 Dec 15 | 109 | -19 | 40 | 6 |
| 30 Sep 15 | 111 | -2 | 40 | 6 |
| 30 Jun 15 | 110 | 0 | 38 | 6 |
| 31 Mar 15 | 109 | 0 | 36 | 6 |
| 31 Dec 14 | 109 | 2 | 35 | 5 |
| 30 Sep 14 | 106 | 2 | 34 | 4 |
| 30 Jun 14 | 106 | 1 | 35 | 4 |
| 31 Mar 14 | 105 | 1 | 35 | 4 |
| 31 Dec 13 | 105 | 1 | 35 | 4 |
| 30 Sep 13 | 106 | 4 | 34 | 2 |
| 30 Jun 13 | 107 | 4 | 35 | 3 |
Quality Earnings: HBIO is currently unprofitable.
Growing Profit Margin: HBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HBIO is unprofitable, and losses have increased over the past 5 years at a rate of 6.5% per year.
Accelerating Growth: Unable to compare HBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: HBIO has a negative Return on Equity (-4.67%), as it is currently unprofitable.